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I think I should start this review with a quote from this book from
the section ‘the ponderables of biochemistry’.
P15
‘Beyond this, however we are adrift (discussion of electro-
chemistry of the body and biochemical processes), as the
mysteries that are the spark of life remain untouched. In other
words, what distinguishes a live cell form a dead one, a live
virus from a killed virus? Or more completely, what in the
ultimate analysis distinguishes a live human being from a dead
one? Can there be, or cannot there be, an inherent bio-physico-
magneto-electro-chemical explanation at the most fundamental
level? Or are we speaking of another domain, entirely, for
example metaphysics, literally beyond or apart from science?’
There is much much more of this for a full 420 pages, indeed a
shorter book would have been very welcome. Given that this is a
book about alternative therapies for cancer, it is perhaps unlikely
to appeal to the career scientist. It is common for example to find
bizzare theories repeated, such as ‘pleomorphism’ p68, which
supposes that harmless bacteria can become disease-producing
viruses. Multiple sources are provided for each theory, but one
must assume that these are not peer-reviewed journals. The merits
(or lack of them) of megadoses of vitamin C are given another
airing here. In fact, the book concludes with a recommendation of
vitamin C as a cheap therapy for cancer.
With such a long book, I have inevitably to be selective while
reviewing. If we look at a section entitled ‘The Navajo and Cancer’
(p351), the author makes a connection between viruses in food (in
this case in poultry) being a cause of cancer, and the taboo on
raising and eating poultry in the Navajo as a factor in the low
incidence of cancer. He also has some interesting observations. He
concludes the second paragraph with
‘Inasmuch as a rigorous system of classification has not been
developed for viruses, they are categorized by size and shape
and include picornaviruses, reoviruses, adenoviruses, calici-
viruses, astroviruses, etc. An unknown factor is whether or not
they may transmute to retroviruses, considered a prime factor
in cancer causation..’
Well size and shape might once have defined virus classification,
but genome sequence analysis long ago replaced such methods. As
for viruses with genetic material of one type transmuting into
retroviruses?
As for the proposal that the low incidence of cancer is related to
poultry consumption, I searched pubmed (the US National library
of medicine database that contains 18 million citations for
biomedical articles dating back to 1948). There is indeed an article
entitled ‘Cancer immunity in the Navajo’ by CG Salsbury dating
from 1956 and other articles suggest that cancer incidence is lower
among the Navajo than in the general population (see a
commentary by D Espey et al (2007): National report to the nation
regarding cancer, 1975–2004, featuring cancer in american indians
and alaska natives. Cancer, 2007, 110, 2119–2152). However,
multiple searches for articles or studies linking cancer with chicken
consumption in the Navajo revealed nothing. Indeed although
some epidemiological studies have linked meat consumption with
cancers in the general population conflicting findings have been
reported. So there seems to be no back up in terms of hard science
for this link of low cancer in the Navajo to chicken consumption.
The worst thing about this is that there is a serious and legitmate
discussion to have about the number of cancers caused by viruses
and bacteria. Probably 15–20% of human cancers are caused by
viruses. Thus, we can think not only of retroviruses, but herpes
viruses, such as human herpes virus 8, which is the causative agent
of Kaposi’s sarcoma, or Hepatitis B and C virus – liver cancers,
papilloma virus – cervical cancers. Of course, the bacterium
Helicobacter pylori was identified as the causative agent in some
stomach cancers. There is plenty of rock solid evidence about
viruses, bacteria and cancer without the need to bring up a theory
that has little information to support it.
With this title one might suppose that the book would lay out
biochemical pathways, at least in diagrammatic form, to illustrate
how inhibitors act. Sadly, this is not the case. There are only two
pathways given at all where surely appropriate use of diagrams and
colour would have greatly simplified the discussions at many points –
causes of cancer for example. The book is also not strong on detailed
biochemistry or chemistry; the table on vitamins and hormones as
enzyme inhibitors is a case in point. The various inhibitors are simply
listed, but without the sources in the table and also critically without
the potency observed. A millimolar strength inhibiton is unlikely to
have any therapeutic significance, a nanomolar one might. The table
lists the molecular formula for each inhibitor, data of no conceivable
value to the argument. There are also outright errors, for example
p418 line 11, ‘ the presence of cancer cells in blood serum may be
indicated by the Ames test’ really? I thought the Ames test was to
determine the potential of chemicals to cause genetic abnormalities
and is conducted on bacteria.
That said, the section in the book on surveying anticancer plant
substances, p233, does provide a survey of the literature, which
might prove useful for some investigators. There is a review of
Judah Folkman’s work on angiogenesis. If the author kept to solid
facts, there might be a reasonable text in here. It is perfectly
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cancers, particularly when one considers how some have been
modified to improve their properties for application in the clinic.
However, even when there is a good story to tell, the author does
not tell it: taxol (paclitaxel), for example (page 212, last paragraph),
is discussed briefly as follows:
‘Also there is Taxol, derived from the bark of the Pacific yew,
an evergreen tree or shrub, notably of the Pacific Northwest.
(Yew wood was once favored by the Indians for bows and other
purposes.) If successful, its relative scarcity versus demand
indicates that chemistry will have to come to the rescue,
especially the speciality known as organic chemistry’
Taxol was approved for ovarian cancer in 1992, and is now used to
treat ovarian, breast and non-small cell lung cancer. Taxol is now
isolated from a specific Taxus cell line cultured to produce the
drug (by the Phyton Biotech company, Ahrensburg, Germany).
This replaced the earlier semisynthetic process. Taxol is a sucessful
antitumour drug, and there is no issue with supply. So this
paragraph is woefully out of date.
I struggle to think who would read this book; patients would be
best advised to contact their doctor/physician and look for
information on the websites of the major cancer organizations
such as Cancer Research UK. Perhaps chemists interested in plant
products might scan the lists of sources, but that is all.
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